Connect
MJA
MJA

Nuclear medicine

Frederick A Khafagi and S Patrick Butler
Med J Aust 2002; 176 (1): . || doi: 10.5694/j.1326-5377.2002.tb04260.x
Published online: 7 January 2002

Through improvements in radiopharmaceuticals and instrumentation, nuclear medicine continues to develop and refine in-vivo approaches for diagnosis (including staging and prognosis) and treatment of disease.


  • 1 Department of Nuclear Medicine and Cardiology, St Andrew's War Memorial Hospital, Brisbane, QLD.
  • 2 Department of Nuclear Medicine, St George's Hospital, Sydney, NSW.


Correspondence: fkhafagi@bigpond.com

  • 1. Scott AM. Current status of positron emission tomography in oncology. Intern Med J 2001; 31: 27-36.
  • 2. Knott JC, Better N. Myocardial perfusion imaging in the evaluation of undiagnosed acute chest pain. Intern Med J 2001; 31: 544-546.
  • 3. Uren RF, Thompson JF, Howman-Giles R. Sentinel lymph node biopsy in patients with melanoma and breast cancer. Intern Med J 2001; 31: 547-553.
  • 4. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma for the prostate: a randomised phase II trial. Lancet 2001; 357: 336-341.
  • 5. Press OW, Eary JF, Gooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934-2942.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.